Supernus Pharmaceuticals (SUPN) Return on Capital Employed: 2012-2024
Historic Return on Capital Employed for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Dec 2024 value amounting to 0.08%.
- Supernus Pharmaceuticals' Return on Capital Employed fell 9.00% to -0.03% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.03%, marking a year-over-year decrease of 9.00%. This contributed to the annual value of 0.08% for FY2024, which is 8.00% up from last year.
- Supernus Pharmaceuticals' Return on Capital Employed amounted to 0.08% in FY2024, which was up 1,904.76% from -0.00% recorded in FY2023.
- Supernus Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.16% during FY2020, with a 5-year trough of -0.00% in FY2023.
- In the last 3 years, Supernus Pharmaceuticals' Return on Capital Employed had a median value of 0.05% in 2022 and averaged 0.04%.
- Per our database at Business Quant, Supernus Pharmaceuticals' Return on Capital Employed dropped by 9bps in 2021 and then climbed by 8bps in 2024.
- Over the past 5 years, Supernus Pharmaceuticals' Return on Capital Employed (Yearly) stood at 0.16% in 2020, then decreased by 9bps to 0.07% in 2021, then declined by 2bps to 0.05% in 2022, then declined by 5bps to -0.00% in 2023, then climbed by 8bps to 0.08% in 2024.